Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al

  1. March 08, 2022

    States Seek $2.2M In Atty Fees For Joining In Shkreli Case

    Four states that helped the Federal Trade Commission win an antitrust case against ex-pharma executive Martin Shkreli are asking a New York federal judge to award $2.2 million in attorney fees, saying the legal battle was complex and costly.

  2. February 04, 2022

    Shkreli's Lifetime Pharma Ban Upheld

    A New York federal judge on Friday rejected Martin Shkreli's objections to the proposed terms of a lifetime ban from the pharmaceutical industry for antitrust violations, agreeing with the Federal Trade Commission that the incarcerated "pharma bro" should be barred from discussing business decisions online or with industry friends.

  3. February 03, 2022

    Lifetime Ban For Shkreli Means Lifetime Ban, FTC Says

    Martin Shkreli cannot hide beyond First Amendment assertions against a lifetime ban from the pharmaceutical industry for antitrust violations, the Federal Trade Commission and state attorneys general told a New York federal judge Wednesday, because the whole point is to prevent future illegal conduct.

  4. February 01, 2022

    Shkreli Fights Scope Of Pharma Industry Ban

    Martin Shkreli is telling a New York federal court that a plan to ban him from the pharmaceutical industry for antitrust violations could chill his First Amendment rights and prevent him from getting jobs that have nothing to do with the case.

  5. January 14, 2022

    'Pharma Bro No More' Shkreli Gets Industry Ban, To Pay $65M

    A New York federal judge on Friday banned Martin Shkreli from participating in the pharmaceutical industry for life and ordered him to pay $64.6 million for increasing the price of a lifesaving drug by 4,000% while blocking generic rivals.

  6. December 14, 2021

    Ex-Vyera CEO Criticizes Shkreli At Drug-Pricing Bench Trial

    Former Vyera Pharmaceuticals CEO Eliseo Salinas told a Manhattan federal judge Tuesday that he thinks Martin Shkreli's 2015 move to dramatically jack up the price of an anti-parasitic drug the company controlled was "crazy," "irresponsible" and "careless."

  7. December 07, 2021

    Former Shkreli Co. Inks Deal Worth Up To $40M With FTC, AGs

    Martin Shkreli's former company and one of its executives settled out of an antitrust lawsuit from the Federal Trade Commission and state attorneys general Tuesday, with a deal in New York federal court.

  8. November 08, 2021

    Shkreli's Old Co. Fair Game For Antitrust Trial, Judge Says

    A New York federal judge handed Martin Shkreli a bitter pill on Friday when she ruled that regulators could bring up evidence the "pharma bro" and one of his former companies jacked up the price of two medications at his upcoming antitrust trial related to another drug.

  9. November 04, 2021

    Shkreli Won't Take The Stand At FTC Antitrust Trial

    Martin Shkreli has informed a Manhattan federal judge that he will not attend a December bench trial on the Federal Trade Commission's allegations that he and his company, Vyera Pharmaceuticals, monopolized the market for a lifesaving parasitic drug.

  10. October 29, 2021

    Shkreli Can't Take The Stand Remotely At FTC Antitrust Trial

    A Manhattan federal judge said Friday that Martin Shkreli must show up to court if he wants to testify at his December trial in a Federal Trade Commission suit alleging he and his company Vyera Pharmaceuticals monopolized the market for a lifesaving parasitic drug.